AngioDynamics posts strong Q4
Interventional device developer AngioDynamics reported robust results in revenue and income for its fiscal 2009 fourth quarter, which ended on May 31.
Net sales in the fourth quarter were $52.8 million, a 13 percent increase over the $46.8 million reported in the fourth quarter last year. The Queensbury, N.Y.-based company said its net income in the fourth quarter was $2.9 million, a strong uptick compared with the $519,000 posted for the same period in fiscal 2008.
For the 2009 fiscal year, the company booked net sales of $195.1 million, an increase of 17 percent over the $166.5 million reported for the prior year. However, net income showed a 10 percent decline to $9.9 million for the year, compared with the $10.9 million in net income recorded for fiscal 2008.
In fiscal 2009, AngioDynamics began operating three business units: Peripheral Vascular, Access and Oncology/Surgery. Peripheral Vascular sales were $22.5 million in the fourth quarter, an increase of 26 percent from the fourth quarter a year ago. Access sales were $17.9 million in the quarter, a decrease of 1 percent from the fourth quarter a year ago, and Oncology/Surgery sales grew 15 percent to $12.4 million from the fourth quarter a year ago.
Net sales in the fourth quarter were $52.8 million, a 13 percent increase over the $46.8 million reported in the fourth quarter last year. The Queensbury, N.Y.-based company said its net income in the fourth quarter was $2.9 million, a strong uptick compared with the $519,000 posted for the same period in fiscal 2008.
For the 2009 fiscal year, the company booked net sales of $195.1 million, an increase of 17 percent over the $166.5 million reported for the prior year. However, net income showed a 10 percent decline to $9.9 million for the year, compared with the $10.9 million in net income recorded for fiscal 2008.
In fiscal 2009, AngioDynamics began operating three business units: Peripheral Vascular, Access and Oncology/Surgery. Peripheral Vascular sales were $22.5 million in the fourth quarter, an increase of 26 percent from the fourth quarter a year ago. Access sales were $17.9 million in the quarter, a decrease of 1 percent from the fourth quarter a year ago, and Oncology/Surgery sales grew 15 percent to $12.4 million from the fourth quarter a year ago.